| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 2,186,243 | $61,291,541 | $28.04 | 13 Jun 2023 | Direct |
| Trevi Therapeutics, Inc. | 10%+ Owner | Common Stock | 12,273,280 | $16,814,393 | $1.37 | 17 Apr 2025 | Direct |
| Marker Therapeutics, Inc. | 10%+ Owner | Common Stock | 1,625,678 | $5,202,170 | $3.20 | 23 Dec 2024 | Direct |
| Metacrine, Inc. | 10%+ Owner | Common Stock | 2,563,257 | $1,204,731 | $0.4700 | 22 Dec 2021 | Direct |
| NeueHealth, Inc. | Director, 10%+ Owner | Common Stock | 0 | $0 | $6.84 | 02 Oct 2025 | Direct |
| Akouos, Inc. | 10%+ Owner | Common Stock | 0 | $12.50 | 30 Nov 2022 | Direct | |
| GENOCEA BIOSCIENCES, INC. | 10%+ Owner | Common Stock | 0 | $1.25 | 25 May 2022 | Direct | |
| NeueHealth, Inc. | Director, 10%+ Owner | Warrant (Right to Buy) | 0 | 02 Oct 2025 | Direct | ||
| Trevi Therapeutics, Inc. | 10%+ Owner | 3.5-Year Common Stock Warrant | 0 | 17 Apr 2025 | Direct |